Views & Analysis Will plausibility reign supreme in Lyrica second medical use... Pharma needs clarity from the Supreme Court on whether the whole scope of a patent claim must be plausible at the time of the application.
News Sandoz separates from Novartis, valued at just over $11bn Sandoz completed its long-heralded separation from Novartis on schedule this morning, with its shares trading at CHF 24 on the SIX Swiss Exchange.
R&D Turning drug development on its head Drug discovery is usually a goal-driven and iterative process, as researchers look for innovative new routes to target particular diseases and study those diseases in afflicted patients to learn ho